|Bid||156.00 x 900|
|Ask||170.23 x 800|
|Day's Range||155.94 - 161.35|
|52 Week Range||63.00 - 181.07|
|Beta (5Y Monthly)||0.49|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 06, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||177.80|
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2021 after market close on Thursday, May 6, 2021. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Liquid biopsies and genomic sequencing that track cancer-related DNA have spawned start-ups and produced eye-popping projections on Wall Street. The diagnostic technology is cutting edge, and the industry is very young.
Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, presents new data at the AACR Virtual Annual Meeting I, April 10-15, 2021, highlighting the use of the company’s proprietary blood tests to advance precision oncology.